

# No Association Between *AGT* Gene Polymorphisms with Hypertension in a South African Population

Jyoti Rajan Sharma<sup>1,\*</sup>, Hannah Fokkens<sup>1,2,\*</sup>, Ria Laubscher<sup>3</sup>, Teke Ruffin Apalata<sup>4</sup>, Sibusiso Cyprian Nomatshila<sup>5</sup>, Samuel Yao Alomatu<sup>6</sup>, Hans Strijdom<sup>2</sup>, Rabia Johnson<sup>1,2</sup>

<sup>1</sup>Biomedical Research and Innovation Platform, South African Medical Research Council, Cape Town, South Africa; <sup>2</sup>Centre for Cardiometabolic Research in Africa, Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; <sup>3</sup>Biostatistics Research Unit, South African Medical Research Council, Cape Town, South Africa; <sup>4</sup>Department of Laboratory-Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University and National Health Laboratory Services, Mthatha, South Africa; <sup>5</sup>Department of Public Health, Faculty of Medicine and Health Sciences, Walter Sisulu University, Mthatha, South Africa; <sup>6</sup>Department of Internal Medicine, Nelson Mandela Central Hospital and Walter Sisulu University, Mthatha, South Africa

\*These authors contributed equally to this work

Correspondence: Rabia Johnson, Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, Cape Town, South Africa, Email [rabia.johnson@mrc.ac.za](mailto:rabia.johnson@mrc.ac.za)

**Purpose:** Hypertension is a leading cause of cardiovascular-related morbidity and mortality worldwide, with a prevalence increasing at an alarming rate in both middle- and low-income countries. Various environmental and genetic factors have been attributed to play a significant role in the increasing prevalence of hypertension. Single nucleotide polymorphisms (SNPs) in the angiotensinogen (*AGT*) gene are reported to have a significant association with hypertension; however, there are limited studies done on South African populations. Therefore, this case-control study aimed to investigate the association between *AGT* SNPs (rs2004776, rs3789678, rs5051 and rs7079) with hypertension in a study population of isiXhosa-speaking participants from the Eastern Cape Province in South Africa.

**Materials and Methods:** The SNPs were genotyped in 250 hypertensive cases and 237 normotensive controls, using TaqMan genotyping assays.

**Results:** For the SNP rs2004776, the frequency of CC genotype (18.4%) and C allele (44%) in hypertensive cases showed no significant differences ( $p = 0.52$ ,  $\chi^2 = 1.32$ ), when compared to the normotensive control group (CC: 19.8% and C allele: 43%). Similar results were obtained for the genotypic and allelic frequencies between hypertensive cases and normotensive controls for rs3789678 ( $p = 0.88$ ,  $\chi^2 = 0.26$ ) and rs5051 ( $p = 0.57$ ,  $\chi^2 = 1.12$ ), and rs7079 ( $p = 0.33$ ,  $\chi^2 = 2.23$ ). These findings demonstrate that there were no significant associations between the SNPs rs2004776, rs3789678, rs7079, rs5051 with hypertension in our study population.

**Conclusion:** These findings suggest that *AGT* gene polymorphisms are not associated with the development of hypertension in the studied population. The present study represents the first genetic report to investigate the *AGT* gene polymorphisms with hypertension in an isiXhosa-speaking South African population.

**Keywords:** hypertension, gene, ACE, *AGT*, polymorphism

## Introduction

Cardiovascular diseases (CVD) are the leading cause of deaths globally, accounting for 19.8 million deaths worldwide in 2022.<sup>1-3</sup> Hypertension drives the global burden of CVD and is a leading cause of cardiovascular-related mortality worldwide, with 1.39 billion affected adults and 10.4 million deaths globally.<sup>4-6</sup> It has emerged as a major public health issue in sub-Saharan Africa, contributing to the region's rising number of early deaths. In South Africa, hypertension has an estimated prevalence of 27–58% and is referred to as a “silent killer”, with 46% of adults being oblivious of their hypertension status.<sup>7-11</sup> The prevalence of hypertension in the rural communities is even higher. According to Sharma

et al,<sup>12</sup> the prevalence of hypertension is 71% in the rural community of Mthatha town in Eastern Cape province, South Africa. Previously, other studies have also highlighted the serious concern of escalating prevalence of hypertension in rural South Africa.<sup>13–15</sup> Despite having an advanced understanding of the pathogenesis and the management of hypertension, there is still a progressive rise in its prevalence.<sup>16</sup>

Various factors, including environmental and genetic factors, have been attributed to play a significant role in the increasing prevalence of hypertension.<sup>12,17–19</sup> Although the exact role of the genetic factors in the regulation of hypertension is still unknown, the genes encoding the main components of the renin-angiotensin-aldosterone system (RAAS) are deemed the most biologically plausible genes.<sup>20,21</sup> The RAAS hormonal system is involved in long-term blood pressure regulation<sup>22,23</sup> and in the aetiology of hypertension by controlling sodium and water retention, oxidative stress, fibrosis, and inflammation, as well as systolic blood pressure.<sup>24</sup> RAAS regulates blood pressure via a cascade of reactions involving the activation of various key proteins.<sup>25</sup>

Proteins such as angiotensinogen (gene: *AGT*, protein: AGT), angiotensin-converting enzyme (gene: *ACE*, protein: ACE), renin, angiotensin I, angiotensin II, angiotensin receptor type I, and angiotensin receptor type II are significant components of RAAS. AGT is a source of all the angiotensin peptides, and renin cleaves AGT into angiotensin.<sup>26,27</sup> The ACE then cleaves angiotensin I into angiotensin II, which causes vasoconstriction and inhibits bradykinin-modulated vasodilation, resulting in elevated blood pressure.<sup>28</sup>

Polymorphisms in the *AGT* gene are reported to have significant associations with hypertension.<sup>17,29,30</sup> The *AGT* (1q42-q43) gene encode for the AGT protein.<sup>31</sup> SNPs within the *AGT* gene, such as rs3789678 (Guanine (G) → Adenine (A) at position 230713736), and rs2004776 (Thymine (T) → Cytosine (C) at position 230712956), rs5051 (Cytosine (C) → Adenine (A) at position 230714126), and rs7079 (Guanine (G) → Thymine (C) at position 230702585), have been investigated for their causal role in hypertension.<sup>32</sup>

In a meta-analysis,<sup>21</sup> it was reported that only a limited number of studies have evaluated the involvement of *AGT* gene with the development of hypertension in African populations. To date, only one study<sup>17</sup> reported a significant association between rs2004776 (*AGT* gene) SNP with hypertension in a Ugandan population. However, other studies performed in African populations exhibited no association between *AGT* gene polymorphisms and risk of developing hypertension.<sup>20,33–35</sup> Furthermore, considering the reduced efficacy of angiotensin receptor blockers (ARBs) in individuals of African ancestry,<sup>36,37</sup> a better understanding of genetic differences is imperative to evaluate disease risk and differential drug response of patients of African ancestry to antihypertensive medications. It has also been suggested that indigenous African populations have higher level of genetic diversity as compared to the other populations of the world.<sup>38</sup> Therefore, the genomic studies of ethnically and genetically diverse populations are critical to understand the differential disease risk in humans.<sup>39</sup> However, there is a paucity of data pertaining to the association of SNPs and the pathogenesis and treatment of hypertension in the rural communities of South Africa.<sup>21,40</sup>

Therefore, the aim of this study was to investigate the putative role of *AGT* gene in hypertension status. This was achieved by genotyping *AGT* SNPs (rs2004776, rs3789678, rs5051 and rs7079) in an isiXhosa-speaking South African population from the Eastern Cape, South Africa. We hypothesize that these polymorphisms are associated with the increased risk of developing hypertension.

## Materials and Methods

### Study Design

The present case-control study included isiXhosa speaking participants from four rural districts (OR Tambo, Alfred Nzo, Chris Hani, Joe Gqabi), and five subdistricts, involving fourteen community health centres in Mthatha in the Eastern Cape Province of South Africa. As per the provincial profile of Eastern Cape,<sup>41</sup> the OR Tambo district has the highest population density of 112 people per km<sup>2</sup>, followed by Alfred Nzo, Chris Hani and lastly Joe Gqabi with a density of 13 people per km<sup>2</sup>. Approximately half of the community health facilities involved in this study were situated in rural areas, defined by the Rural Development Framework as sparsely populated areas in which people depend on natural resources or farming, including villages and small towns dispersed throughout these areas". The percentage of persons aged 0–34 years varied from 36–40%; however, OR Tambo and Alfred Nzo had 13% of the population in 35–64 age group, while

this percentage was higher in both Chris Hani and Joe Gqabi districts (approximately 15%). The proportion of population over 65 years was the highest in Chris Hani district (8.6%) followed by Alfred Nzo (7.9%), Joe Gqabi (7.5%), and OR Tambo (6.5%). All the district municipalities are inhabited mainly by the black African population. Sex ratio depicted that at young ages (0–19 years), there were more males as compared to females; however, the age group >20 years reported more females.

The highest percentage of residents in these districts reported that they speak isiXhosa language and are affiliated to Christianity. In OR Tambo and Chris Hani and Alfred Nzo district over 60% aged 18 years were never married. However, Joe Gqabi had the lowest percentage of never married persons.

## Eligibility Criteria

This study included only adult participants (over 18 years of age or more) and excluded pregnant women and those who were reluctant to participate.

## Ethical Clearance

The study was conducted following the Declaration of Helsinki<sup>42</sup> and approved by the Institutional Review Board (or Ethics Committee) of SAMRC (SAMRC: EC028-8/2020), Water Sisulu University (073/15) and Stellenbosch University Human Research ethics committee (S22/05/095). The essential information about the participants' rights, research purpose, and research process was provided to the participants in two different languages (English and isiXhosa) before obtaining the informed consent.

## Data Collection

Data were collected via the World Health Organization (WHO) STEPwise amended questionnaire and deposited into the Research Electronic Data Capture system (REDCap<sup>TM</sup>). Data collected included sociodemographic factors (age, gender, ancestry) and anthropometric measurements (waist circumference, hip circumference, height, weight) and blood pressure measurements (systolic blood pressure, diastolic blood pressure). The most important determinants of hypertension from other studies<sup>43</sup> and significant determinants identified in the previous study on the same population were included.<sup>12</sup>

## BMI and Obesity Profiles

Anthropometric measurements such as body weight and height were used to calculate body mass index (BMI) and waist-to-hip ratio (WHR). A conventional beam balance was used to weigh barefoot participants in light clothing to the nearest 0.1 kg. On a mounted stadiometer, height was measured to the nearest 0.1 cm, and BMI was determined by using the following formula:  $\text{weight}/(\text{height})^2$ . According to the WHO standards, participants were categorized as normal, overweight, and obese.<sup>44,45</sup> Participants were considered overweight if BMI was 25–29.9 kg/m<sup>2</sup> and were categorized as obese if their BMI was  $\geq 30.0$  kg/m<sup>2</sup>. Participants with BMI  $\leq 25$  were either classified as normal or underweight. The waist circumference measurement was taken approximately halfway between the lower edge of the last palpable rib and the top of the iliac crest.<sup>46</sup> The measurement of the hip circumference was obtained around the broadest part of the buttocks. The waist to hip ratio was calculated using the following formula: waist circumference/hip circumference.

## Diagnosis of Type 2 Diabetes Mellitus (T2D)

A blood sample was taken from each participant after an overnight fast. The diagnosis of T2D was confirmed according to the criteria of the American Diabetic Association, 2022.<sup>47,48</sup> Participants were categorized as normal (fasting blood sugar level < 5.6 mmol/L), prediabetic (fasting blood sugar level between 5.6 - to 6.9 mmol/L), and diabetic (fasting blood sugar level >7 mmol/L).

## Measurement and Definition of Blood Pressure

Before blood pressure measurement, participants were asked to sit at rest for approximately five minutes. Blood pressure was measured using a slight touch ST-401 blood pressure monitor based on standard operating procedures. Diagnosis of hypertension status was defined as per the South African Hypertension Society guidelines (Seedat, Rayner and Veriava,

2014). Participants were categorised as follows: (1) Normal blood pressure (systolic blood pressure (SBP): <120 mm Hg and diastolic blood pressure (DBP) < 80mm Hg (2) optimal blood pressure (SBP: 120–129 mm Hg and DBP < 80 mm Hg), (3) High Normal (SBP: 130–139 mm Hg and DBP: 80–89 mm Hg), and (4) Hypertension (HTN) grade 1 SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg. Based on these guidelines, the participants in the current study were categorized as normotensive (SBP ≤ 120mm Hg; DBP < 80mmHg) or hypertensive based on the values of blood pressure (SBP ≥ 140–159mm Hg or DBP: ≥90–99mm Hg) or if they are already on prescribed antihypertensive medication. The diagnosis of hypertension was confirmed after evaluating the patients' medical history, symptoms, and prescribed medication for three months.

# Sampling Procedure

We enrolled a total of 487 participants (237 normotensive controls and 250 hypertensive cases). With written and informed consent, venous blood (5 mL) was collected in EDTA tubes (anticoagulant). The samples were stored at –80 degrees Celsius until further analysis. A blood sample was also taken after an overnight fast to measure the glucose levels.

# DNA Extraction and Genotyping

Genomic DNA was extracted from 1mL of whole blood sample, using the QIAamp Blood Midi Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted DNA was quantified on the NanoDrop Spectrophotometer (Nanodrop Technologies). The selection of the variants (rs2004776, rs3789678, rs5051, rs7079) of *AGT* gene was based on the previous literature and with minor allele frequency (MAF) >1% in the population upon referring to the public databases. There is paucity of data on the association of these SNPs in African population. The genotypes were determined using quantitative Real-Time PCR (qRT-PCR) with TaqMan genotyping assays (Applied Biosystems, Massachusetts, United States). Four SNPs located in *AGT* (rs2004776, rs3789678, rs5051, rs7079) were included in the study, and primers were designed as shown in Table 1. The File Builder tool was then used to order primers from Applied Biosystems and synthesized according to the specifications. The TaqMan custom genotyping assay probes (x40) were assigned the labels VIC and FAM to the sequences below (Table 1).

All samples were diluted to a final concentration of 10 ng/μL and aliquoted individually (4.75 μL) in each well of a 96 well plate. A PCR master mix was prepared by adding 5 μL of TaqPath ProAmp Master Mix and 0.25 μL of 40X TaqMan SNP Genotyping Assay in a total volume of 10 μL, according to the manufacturer's instructions (Applied Biosystems). A volume of 5.25 μL of the master mix was added to each well, yielding a final volume of 10 μL (4.75 μL sample + 5.25 μL master mix) in each well. Negative control of the same volume was also added with each PCR run. The Quant studio 5 (Applied Biosystems, Massachusetts, United States) was used for the PCR amplification. PCR parameters were as follows: pre-read for 30s at 60°C (hold); initial denaturation for 5 min at 95°C (hold); denaturation for 5s at 95°C for 40 cycles; annealing/extension for 30s at 60°C for 40 cycles; post-read for 30s at 60°C (hold). All samples were

**Table 1** Details of Single Nucleotide Polymorphisms Assays

Gene	Variant	Nucleotide Position	SNP Sequence	Global MAF	AFR MAF
AGT	rs2004776	Chromosome I 230,712,956	GGCTGAATGCTAAAGGTGAAGATGA [C/T] GGCTCATGCTCCTGTGGTGCCTGCC	C=0.59 T=0.41	C=0.51 T=0.49
	rs3789678	Chromosome I 230,713,736	CCTTCCCTCCAGCCCCAATTCCTG [C/T] ACAAGCCCTGCTATTCCTCCTGATG	C=0.82 T=0.18	C=0.75 T=0.25
	rs5051	Chromosome I 230,714,126	CCAGAACACGGCAGCTTCTTCCCC [C/T] GGCCGGGTCACGATGCCCTATTAT	T=0.71 C=0.29	T=0.92 C=0.08
	rs7079	Chromosome I 230,702,585	ACACAAGGGAGAAATAACCAGCTAT [G/T] GTTCCGCATTCAAACAGAAATTCAG	G=0.81 T=0.19	G=0.93 T=0.07

**Notes:** Bold letters indicate the SNP of interest in each sequence. Global MAF: minimum allele frequency at the global level. AFR MAF: minimum allele frequency in Africa.

genotyped in duplicate. The QuantStudio™ 7 design and analysis software was for base calling and visualization of the genotyping data ([Supplementary Figure S1](#)).

## Statistical Analysis

Clinical and anthropometric parameters were presented as mean  $\pm$  standard deviation (SD) if normally distributed and as median (Q1–Q3) if skewed. Shapiro-Francia  $W'$  test was used to assess normality. In the case of normally distributed parameters, Student's  $t$ -test was used, and for skewed parameters, median regression (QREG in STATA) was used to assess group differences (hypertensive vs control group), for the pooled sample and within gender. Allelic and genotypic frequencies were compared. The conformity of genotype distributions was evaluated using Hardy-Weinberg equilibrium. The association between hypertension and genotype was tested using the chi-squared test and odds ratio with 95% confidence intervals was calculated to evaluate allelic association with the disease status. Logistic regression models enabled us to adjust for age, gender, and waist circumference (WC). This was done for the various inheritance models (dominant, recessive, and codominant), and the multivariate model. Statistical analysis was performed using the STATA16 (Software for Statistics and Data Science, package SE).

## Results

The demographic, clinical, and anthropometric parameters of 487 participants (237 normotensive controls and 250 hypertensive cases) are presented in [Table 2](#). The hypertensive cohorts had a higher age mean of 55 years as compared to normotensive controls (mean = 41.6 years), with the differences being significant in the total pooled ( $p < 0.001$ ) groups. All parameters were significantly higher ( $p < 0.05$ ) in hypertensive cases as compared to normotensive controls in the total pooled sample. Furthermore, it was demonstrated that gender is not a statistically significant predictor of developing hypertension ( $p = 0.320$ ).

**Table 2** Comparison of Various Parameters (Mean  $\pm$  SD) in Total Pooled, Male, and Female Hypertensive Cases and Normotensive Controls

Variable	Hypertensive Cases N=250	Normotensive Controls N=237	Total N=487	p-value
<b>Gender</b>				
<b>Female (N)</b>	205 (83.3%)	186 (79.8%)	391 (81.6%)	0.320
<b>Male (N)</b>	41 (16.7%)	47 (20.2%)	88 (18.4%)	
<b>Age (years)</b>	55.13 (13.08)	41.64 (12.74)	48.54 (14.56)	<0.001*
<b>BMI (kg/m<sup>2</sup>)</b>	32.35 (6.79)	27.98 (6.65)	30.11 (7.06)	<0.001*
<b>WC (cm)</b>	102.03 (13.91)	91.06 (13.66)	96.67 (14.83)	<0.001*
<b>HC (cm)</b>	113.67 (13.91)	107.78 (13.49)	110.78 (14.00)	<0.001*
<b>WHR</b>	0.90 (0.09)	0.85 (0.09)	0.87 (0.09)	<0.001*
<b>Blood Glucose (mmol/L)</b>	6.58 (3.13)	5.76 (2.06)	6.17 (2.68)	<0.001*
<b>SBP (mm Hg)</b>	142.88 (21.22)	117.64 (10.78)	130.50 (21.10)	<0.001*
<b>DBP (mm Hg)</b>	89.64 (11.80)	75.69 (7.18)	82.80 (12.03)	<0.001*

**Note:** \* $p < 0.05$  statistically significant.

**Abbreviations:** BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; WHR, Waist to Hip Ratio WC – waist circumference; HC, Hip circumference.

## Genotyping and Allele Frequencies

A univariate analysis was used to identify SNP association with the disease status, and the data were adjusted for age, BMI and waist circumference. The genotype distribution conformity was assessed using the Hardy-Weinberg equilibrium, and it was observed that genotypes in both cases and controls were in equilibrium. Genotypic and allelic frequencies in hypertensive subjects and normotensive controls for the studied SNPs are given in Table 3. For the

**Table 3** Genotypic Frequency and Allelic Frequency Distribution for AGT gene Polymorphisms in Hypertensive Cases and Normotensive Controls

Genotype/allele Frequency	Hypertensive Cases N=250	Normotensive Controls N=237
<b>rs2004776</b>		
CC (homozygous wild type)	46 (18.4%)	47 (19.8%)
CT (heterozygous)	118 (47.2%)	120 (50.6%)
TT(homozygous mutant type)	86 (34.4%)	70 (29.5%)
C	44%	43%
T	53%	60%
Univariate analysis	OR=1.14 (0.79–1.63)   p=0.52, $\chi^2=1.32$	
<b>rs3789678</b>		
CC (homozygous wild type)	101 (40.4%)	93 (39.2%)
CT (heterozygous)	113 (45.2%)	106 (44.7%)
TT (homozygous mutant type)	36 (14.4%)	38 (16.0%)
C	60%	65%
T	37%	38%
Univariate analysis	OR=0.94 (0.65–1.36)   p=0.88, $\chi^2=0.26$	
<b>rs5051</b>		
TT (homozygous wild type)	218 (87.2%)	204 (86.1%)
CT (heterozygous)	32 (12.8%)	32 (13.5%)
CC (homozygous mutant type)	0 (0.0%)	1 (0.4%)
T	90%	90%
C	7%	7%
Univariate analysis	OR=1.13 (0.56–2.29)   p=0.57, $\chi^2=1.12$	
<b>rs7079</b>		
GG (homozygous wild type)	227 (90.8%)	209 (88.2%)
GA (heterozygous)	7 (2.8%)	13 (5.5%)
AA (homozygous mutant type)	16 (6.4%)	15 (6.3%)
G	88%	95%
A	9%	8%
Univariate analysis	OR=0.85 (0.45–1.61)   p=0.33, $\chi^2=2.23$	

Abbreviation: OR, Odds Ratio for allele frequency and  $\chi^2$  for genotype frequency.



SNP rs2004776, no significant differences were observed for genotypic and allelic frequencies between hypertensive cases and normotensive controls ( $p = 0.52$ ,  $\chi^2 = 1.32$ ). Similarly, the genotypic and allelic frequencies between hypertensive cases and normotensive controls were not significantly different for rs3789678 ( $p = 0.88$ ,  $\chi^2 = 0.26$ ) and rs5051 ( $p = 0.57$ ,  $\chi^2 = 1.12$ ), and rs7079 ( $p = 0.33$ ,  $\chi^2 = 2.23$ ). Univariate analysis demonstrated that the studied SNPs (rs2004776, rs3789678, rs5051, and rs7079) were not associated with the risk of developing hypertension.

## Inheritance Models and Univariate Analysis

Various hypothetical inheritance models were used to analyse the association of each SNP with the disease status (Table 4). For SNP rs2004776, under the dominant ( $p = 0.609$ ), recessive ( $p = 0.865$ ), and codominant ( $p = 0.577$ ) inheritance models, the T allele did not confer any risk of developing hypertension. The analysis of rs3789678 polymorphism also demonstrated no significant association of the risk allele with disease status, under dominant ( $p = 0.356$ ), recessive ( $p = 0.674$ ), and codominant ( $p = 0.545$ ) inheritance models. Similar results were obtained for the SNP rs7079 under the dominant ( $p = 0.912$ ), recessive ( $p = 0.953$ ), and codominant model ( $p = 0.805$ ). For rs5051, the number of subjects with genotype CC was very low; therefore, this SNP was not included in the further analysis.

## Multivariate Analysis

Multivariate logistic regression was used to collectively analyse all the three polymorphisms (Table 5). As interpreted from the unadjusted odds ratio, there was no significant association ( $p > 0.05$ ) between any of the polymorphisms with risk of developing hypertension. The results were the same, after adjusting for age, and waist circumference.

## Discussion

Hypertension is a major public health problem, particularly in Africa, contributing significantly to the increasing number of premature deaths in this region.<sup>49</sup> Due to the complex genetic diversity, and inheritance patterns in Africa, genetic studies in these populations could reveal vital information about the influence of genes on human health and disease susceptibility.<sup>50</sup> Many studies have investigated the association of *AGT* and SNPs with hypertension in various populations; the contradictory outcomes of these studies necessitate the replication of SNP association studies in larger groups

**Table 4** Association Between AGT Polymorphisms and Hypertension Status in Different Inheritance Models

	Unadjusted OR (95% CI)	Unadjusted p	aOR (95% CI)	Adjusted p
<b>rs2004776</b>				
CC vs CT+TT Dominant model	0.91 (0.58–1.43)	0.688	1.16 (0.66–2.04)	0.609
TT vs CT+CC Recessive model	1.25 (0.85–1.83)	0.251	1.04 (0.65–1.68)	0.865
CT vs CC+TT Codominant model	0.87 (0.61–1.24)	0.449	0.88 (0.57–1.37)	0.577
<b>rs3789678</b>				
CC vs CT+TT Dominant model	1.05 (0.73–1.50)	0.794	1.24 (0.79–1.94)	0.356
TT vs CT+CC Recessive model	0.88 (0.54–1.45)	0.616	0.88 (0.47–1.62)	0.674
CT vs CC+TT Codominant model	1.01 (0.71–1.45)	0.916	0.87 (0.56–1.36)	0.545
<b>rs7079</b>				
GG vs GA+AA Dominant model	1.32 (0.74–2.37)	0.347	1.04 (0.52–2.06)	0.912
AA vs GA+GG Recessive model	1.01 (0.49–2.10)	0.974	1.02 (0.44–2.40)	0.953
GA vs GG+AA Codominant model	0.50 (0.19–1.27)	0.143	0.87 (0.30–2.56)	0.805

**Abbreviations:** aOR, Adjusted Odd's Ratio (adjusted for age, and BMI); CI, Confidence Intervals.

**Table 5** Multivariate Logistic Regression Model of Various SNPs (*AGT* Gene) Associated with Hypertension

	Unadjusted OR (95% CI)	Unadjusted p	aOR (95% CI)	Adjusted p
<b>rs2004776</b>				
CT	1.00 (0.62–1.62)	0.985	0.88 (0.49–1.56)	0.663
TT	1.25 (0.75–2.09)	0.870	1.10 (0.59–2.04)	0.748
<b>rs3789678</b>				
CT	0.98 (0.66–1.44)	0.925	0.82 (0.52–1.31)	0.426
TT	0.87 (0.51–1.49)	0.617	0.92 (0.49–1.75)	0.821
<b>rs7079</b>				
GA	0.49 (0.19–1.26)	0.143	0.87 (0.29–2.59)	0.809
AA	0.98 (0.47–2.03)	0.961	0.93 (0.39–2.20)	0.875

**Abbreviations:** aOR, Adjusted Odds Ratio (adjusted for age, and waist circumference); CI, Confidence Intervals.

from diverse populations around the world. To our knowledge, this is the first study to investigate the association of *AGT* polymorphisms (rs2004776, rs3789678, rs5051 and rs7079) with hypertension in a study population of isiXhosa-speaking individuals of the Eastern Cape Province, South Africa.

Consistent with other studies,<sup>12,18,51</sup> the results of the present study indicate that advanced age is a risk factor in the development of hypertension. The mean age of hypertensive individuals was significantly higher than normotensive individuals. It has been postulated that increased vascular resistance may contribute to higher prevalence of hypertension among older adults.<sup>52,53</sup>

In line with previous studies, findings from the current study strongly indicate that obesity could be a risk factor in the development of hypertension in the studied population of the Eastern Cape. The present study observed significantly higher BMI in the hypertensives as compared to the normotensive controls. Previous research has found that having a higher BMI is a major risk factor for hypertension and that there is a linear association between BMI and hypertension.<sup>18,54,55</sup> Obesity and visceral adiposity have also been shown to be positively linked with the RAAS, which regulates blood pressure.<sup>56–59</sup> The mean waist circumference observed in the current study was significantly elevated in the hypertensive groups compared to the normotensive control group. According to the new cut-off values<sup>60</sup> ( $\geq 95.25$  cm and  $\geq 89.45$  cm for males and females, respectively), the waist circumference of the hypertensive group surpasses the cut-off values; therefore, they are at greater risk of developing metabolic syndrome and hypertension.<sup>61</sup>

The mean hip circumference observed in the current study was significantly higher in the pooled hypertensive group compared to the normotensive controls. Although hip circumference is not directly linked with hypertension risk, it is used to calculate the waist–hip ratio, which is suggested to be a more predictive tool for the developing hypertension than waist and hip circumferences alone.<sup>46</sup>

The present study observed significantly higher fasting blood glucose levels in the hypertensive group than the normotensive control group. Another study found that diabetic individuals have nearly twice the risk of developing hypertension compared to non-diabetic individuals.<sup>12</sup> Due to their overlapping metabolic pathways and risk factors, it is well known that there is significant commonality between hypertension and diabetes.<sup>62,63</sup> Furthermore, a high BMI (overweight/obesity) is frequently linked to insulin resistance, which has substantial consequences for the development of type 2 diabetes mellitus.<sup>64,65</sup> Obesity and type 2 diabetes mellitus are associated with an increased risk of death from cardiovascular illnesses.<sup>11,66–68</sup>

In the current study, genotypic, dominant, and recessive models showed no significant association between the various *AGT* SNPs (rs2004776, rs3789678, rs5051 and rs7079) and risk of developing hypertension in this study population.

Previous studies investigating the association between *AGT* polymorphisms and hypertension are limited and have reported conflicting results (Table 6).



**Table 6** Association of AGT Polymorphisms and Hypertension in Various Populations

SNP rs Number	Nucleotide Position	Nucleotide Substitution	Cases	Controls	Population	Association	Country	References
rs2004776	Chromosome 1:230,712,956	Ancestral C C>T	782	2099	East African population	Yes	Uganda	[17]
			215	230	Indian Population	Yes	India	[69]
rs3789678	Chromosome 1:230,713,736	Ancestral C C>T	905	905	Han Chinese population	Yes	China	[70]
			202	222	Indian population	Yes	Delhi	[32]
rs7079	Chromosome 1:230,702,585	Ancestral G G>A	3521	1596	Native Saudi individuals	Yes	Saudi Arabia	[71]
rs5051	Chromosome 1:230,714,126	Ancestral T T>C	652	780	Northern Han Chinese population	Yes	China	[72]
			2203	2354	White African American	Yes	US	[73]
			3521	1596	Native Saudi individuals	No Yes	Saudi Arabia	[71]

Consistent with our results, a study<sup>74</sup> reported no association of rs2004776 with the development of hypertension in a Chinese Han population, with a similar sample size as the current study. However, in that study authors had investigated the pregnancy-induced hypertension, thus the conclusions drawn may not directly applicable to the current study. In contrast, other studies performed in African,<sup>17</sup> North American<sup>75</sup> and Indian<sup>69</sup> populations, respectively, reported that the TT genotype (rs2004776) increased susceptibility to hypertension. However, the frequency of the minor allele found in the current study (T-allele) of rs2004776 (53%) is in line with that reported the African population (46%)<sup>17</sup> but significantly higher than the frequencies observed in two Asian populations (10–30%)<sup>69,74</sup> and a North American population (22–24%).<sup>75</sup>

The AGT rs3789678 polymorphism is not associated with hypertension in our study, and it is inconsistent with the findings reported in an Indian population.<sup>32</sup> Authors identified a protective effect of this SNP in susceptibility risk of developing hypertension in an Indian population. However, three studies performed in Chinese Han populations have reported an association of rs3789678 polymorphism with an increased risk of developing hypertension.<sup>70,74,76</sup> The minor allele (T-allele) frequency of rs3789678 reported in the present study is higher (37%) compared to the frequencies observed in the four Asian populations (2–14%).<sup>32,70,74,77</sup>

There was no association of rs7079 polymorphism and risk of developing hypertension in our study population. These results are contrary to the results reported by Mopidevi et al, 2013,<sup>78</sup> where the rs7079 SNP showed an association with elevated BP. The C to A substitution increased circulating AGT levels by altering microRNA binding to the 3'-UTR of AGT.<sup>78,79</sup> Micro RNAs are small noncoding RNAs of 20–22 nucleotides and have been demonstrated to regulate gene expression and various key cellular activities.<sup>80,81</sup> A study<sup>82</sup> showed that the nucleotide sequence of AGT gene with C allele has perfect base pairing with two micro RNAs (miR-584 and miR-31), resulting in the posttranscriptional modification of AGT gene and downregulating its expression, however, the presence of A allele in AGT gene sequence leads to destabilization of the base pairing with micro RNA and lead to increased AGT expression. Their results confirm that rs7079 is a functional SNP, this is consistent with the previous findings which illustrated that rs7079 is associated with non-alcoholic steatohepatitis,<sup>83</sup> body fat distribution<sup>84</sup> and coronary artery disease.<sup>71</sup> Variants of rs7079 have also found to influence BP responses to anti-hypertensive treatments, such as benazepril in a Chinese cohort.<sup>85</sup> Current literature does not provide much information on the role of this SNP in hypertension. The minor allele frequency in the

current study is 9% which is like the frequency observed in the African population, however, significantly lower than the minor frequencies reported (ENSEMBL) in American (19%), European (33%) South Asian populations (29%).

The *AGT* rs5051 did not demonstrate any association with hypertension in the present study population. Similar findings were shown in a Pacific Island study, although the presence of T allele was associated with probability of having higher SBP compared to C allele carriers<sup>86</sup> However, in a Saudi study,<sup>71</sup> and in China,<sup>72</sup> an association was reported between rs5051 and HTN. Another study also reported a significant association between the G allele of rs5051 and treatment-resistant hypertension (TRH) among Caucasians (GenHat cohorts), however, African Americans<sup>73</sup> did not report any association. The minor allele frequency is 7% in the current study which is almost the same as reported in African population (8%; ENSEMBL) but significantly lower than the frequencies observed in American population (35%), European population (59%) and South Asian populations (36%).

The conflicting results of these variants in different populations possibly highlight the genetic variability in the practical relevance of these findings globally. Several factors could be responsible for these discrepancies. One of the most likely explanations is the probability of the variation in the minor allele frequencies among different populations studied.

There are some limitations in this study that can be improved in future research work. The current study had a small sample size; a larger sample size would increase the reliability and validity of results. This study only investigated the association of four SNPs of *AGT* gene. More *AGT* SNPs should be evaluated to explore the functional consequences of each variant and their contribution to the disease risk.

## Conclusions

In conclusion, the genotype distributions of *AGT* polymorphisms do not influence the risk of developing hypertension in the current study population of isiXhosa-speaking South Africans, and further analysis is needed on a larger sample size. Additionally, more research on study populations from other regions of South Africa is warranted to corroborate the current findings. Other polymorphisms in the coding and promoter regions of these candidate genes should also be evaluated in the context of the complex ancestral heritage of the South African population to determine their functional importance and impact on hypertension. More detailed investigations of these variants may aid in our understanding of genetic susceptibility factors in diverse populations, allowing for better prevention strategies and therapies.

## Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

## Acknowledgments

We would like to thank the staff of primary health care facilities in Mthatha Town for their support and contributions towards successfully completing the study. We would also like to acknowledge Mr. Faleni for his assistance in collecting the samples.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

This research was funded by a Strategic Health Innovation partnership grant (SHIP-RFA-01-2019), SAMRC baseline funding, DSI funding and, CPRR (SRUG2203301281).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Mensah GA, Fuster V, Murray CJL, Roth GA Global burden of cardiovascular diseases and risks collaborators. Global burden of cardiovascular diseases and risks, 1990–2022. *J Am Coll Cardiol*. 2023;82(25):2350–2473. doi:10.1016/j.jacc.2023.11.007
2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. *J Am Coll Cardiol*. 2020;76(25):2982–3021. doi:10.1016/j.jacc.2020.11.010
3. Mendis S, Davis S, Norrving B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. *Stroke*. 2015;46(5):e121–e122. doi:10.1161/STROKEAHA.115.008097
4. Collaborators GRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013; 2015.
5. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. *Lancet*. 2020;395(10226):795–808. doi:10.1016/s0140-6736(19)32008-2
6. Boateng EB, Ampofo AG. A glimpse into the future: modelling global prevalence of hypertension. *BMC Public Health*. 2023;23(1):1906. doi:10.1186/s12889-023-16662-z
7. Gómez-Olivé FX, Ali SA, Made F, et al. Regional and sex differences in the prevalence and awareness of hypertension: an H3Africa AWI-Gen study across 6 sites in sub-Saharan Africa. *Global Heart*. 2017;12(2):81–90. doi:10.1016/j.gheart.2017.01.007
8. Ibrahim MM, Damasceno A. Hypertension in developing countries. *Lancet*. 2012;380(9841):611–619. doi:10.1016/S0140-6736(12)60861-7
9. Kallehoff JP, Oparil S. The story of the silent killer: a history of hypertension: its discovery, diagnosis, treatment, and debates. *Curr Hypertens Rep*. 2020;22(9):72. doi:10.1007/s11906-020-01077-7
10. O'Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. *Int J Clin Chem*. 2017;465:131–143. doi:10.1016/j.cca.2016.12.014
11. Woodiwiss AJ, Orchard A, Mels CM, et al. High prevalence but lack of awareness of hypertension in South Africa, particularly among men and young adults. *J Human Hypertens*. 2023;37:1–9. doi:10.1038/s41371-022-00751-4
12. Sharma JR, Mabhida SE, Myers B, et al. Prevalence of hypertension and its associated risk factors in a rural black population of Mthatha Town, South Africa. *Int J Environ Res Public Health*. 2021;18(3):1215. doi:10.3390/ijerph18031215
13. de Ramirez SS, Enquobahrie DA, Nyadzi G, et al. Prevalence and correlates of hypertension: a cross-sectional study among rural populations in sub-Saharan Africa. *J Human Hypertens*. 2010;24(12):786–795. doi:10.1038/jhh.2010.14
14. Bosu WK, Reilly ST, Aheto JMK, Zucchelli E. Hypertension in older adults in Africa: a systematic review and meta-analysis. *PLoS One*. 2019;14(4):e0214934. doi:10.1371/journal.pone.0214934
15. Adeniyi OV, Yogeswaran P, Longo-Mbenza B, Goon DT. Uncontrolled hypertension and its determinants in patients with concomitant type 2 diabetes mellitus (T2DM) in rural South Africa. *PLoS One*. 2016;11(3):e0150033. doi:10.1371/journal.pone.0150033
16. Nkeh-Chungag BN, Stewart S. Review of elevated blood pressure in sub-Saharan Africa. *Lancet Glob Health*. 2023;11(8):e1148–e1149. doi:10.1016/S2214-109X(23)00283-8
17. Kayima J, Liang J, Natanzon Y, et al. Association of genetic variation with blood pressure traits among East Africans. *Clin Genet*. 2017;92(5):487–494. doi:10.1111/cge.12974
18. Wandai ME, Norris SA, Aagaard-Hansen J, Manda SO. Geographical influence on the distribution of the prevalence of hypertension in South Africa: a multilevel analysis. *Cardiovasc J Afr*. 2020;31(1):47–54. doi:10.5830/cvja-2019-047
19. Cunningham PN, Chapman AB. The future of pharmacogenetics in the treatment of hypertension. *Future Med*. 2019;2019:129–132.
20. Tchelougou D, Kologo JK, Karou SD, et al. Renin-angiotensin system genes polymorphisms and essential hypertension in Burkina Faso, West Africa. *Internat J Hypert*. 2015;2015:1–7. doi:10.1155/2015/979631
21. Mabhida SE, Mashatola L, Kaur M, et al. Hypertension in African populations: review and computational insights. *Genes*. 2021;12(4):532. doi:10.3390/genes12040532
22. Tigerstedt R, Bergman P. Niere und Kreislauf I. *Skandinavisches Archiv Für Physiol*. 1898;8(1):223–271. doi:10.1111/j.1748-1716.1898.tb00272.x
23. Martyniak A, Tomasiak PJ, Zarnescu EC, Costea R. A new perspective on the renin-angiotensin system. *Diagnostics*. 2022;13:1. doi:10.3390/diagnostics13010016
24. Goldblatt H, Lynch J, Hanzal R, Summerville W. The production of persistent elevation of systolic blood pressure by means of renal ischemia. *J Exp Med*. 1934;59:347–379. doi:10.1084/jem.59.3.347
25. Zaporowska-Stachowiak I, Hoffmann K, Bryl W, Minczykowski A. Aliskiren—an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. *Arch Med Sci*. 2014;10(4):830. doi:10.5114/aoms.2013.34723
26. Lu H, Cassis LA, Vander Kooi CW, Daugherty A. Structure and functions of angiotensinogen. *Hypertens Res*. 2016;39(7):492–500. doi:10.1038/hr.2016.17
27. Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme: i. Biochemistry and structure of the gene. *J Hypert*. 1993;11(5):471–476. doi:10.1097/00004872-199305000-00001
28. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). *Hypertension*. 1997;30(3):535–541. doi:10.1161/01.HYP.30.3.535
29. De Azevedo MJ, Dalmáz CA, Caramori MLA, et al. ACE and PC-1 gene polymorphisms in normoalbuminuric Type 1 diabetic patients: a 10-year prospective study. *J Diabet Complicat*. 2002;16(4):255–262. doi:10.1016/S1056-8727(01)00185-4
30. Jiang X, Sheng H, Li J, et al. Association between renin-angiotensin system gene polymorphism and essential hypertension: a community-based study. *J Human Hypertens*. 2009;23(3):176–181. doi:10.1038/jhh.2008.123
31. Dickson ME, Sigmund CD. Genetic basis of hypertension: revisiting angiotensinogen. *Hypertension*. 2006;48(1):14–20. doi:10.1161/01.HYP.0000227932.13687.60
32. Gunda P, Nagalingam S, Tirunilai P. Role of tagged SNPs of the AGT gene in causing susceptibility to essential hypertension. *Ann Clin Exp Hypertens*. 2016;38(6):520–525. doi:10.3109/10641963.2016.1163371

33. Meroufel DN, Médiène-Benchekor S, Dumont J, Benhamamouch S, Amouyel P, Brousseau T. A study on the polymorphisms of the renin-angiotensin system pathway genes for their effect on blood pressure levels in males from Algeria. *J Renin Angiot Aldost Syst.* **2014**;15(1):1–6. doi:10.1177/1470320313485898
34. Amrani A, Baba Hamed MB, Mesli Talebbendiab F. Association study between some renin-angiotensin system gene variants and essential hypertension in a sample of Algerian population: case control study. *Ann. Biol. Clin.* **2015**;73(5):557–563. doi:10.1684/abc.2015.1069
35. Kooffreh ME, Anumudu CI, Kumar PL. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene and the risk of hypertension among residents of two cities, South-South Nigeria. *Adv Biomed Res.* **2014**;3:118. doi:10.4103/2277-9175.133184
36. Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and  $\beta$ -adrenergic blockers? A systematic review. *BMC Med.* **2013**;11(1):1–16. doi:10.1186/1741-7015-11-141
37. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. *Hypertension.* **2004**;43(3):566–572. doi:10.1161/01.HYP.0000118019.28487.9c
38. Gomez F, Hirbo J, Tishkoff SA. Genetic variation and adaptation in Africa: implications for human evolution and disease. *Cold Spring Harbor Perspect Biol.* **2014**;6(7):a008524. doi:10.1101/cshperspect.a008524
39. Skeete J, DiPette DJ. Genetics of hypertension: implications of single nucleotide polymorphism (s) in African populations and beyond. *J Clin Hypertens.* **2018**;20(3):496. doi:10.1111/jch.13249
40. Mabhida SE, Muhamed B, Sharma JR, et al. Methylenetetrahydrofolate reductase polymorphism (rs1801133) and the risk of hypertension among African populations: a narrative synthesis of literature. *Genes.* **2022**;13(4):631. doi:10.3390/genes13040631
41. Africa SS. Provincial profile: eastern cape community survey. Report No. 03-01-08; **2016**. Available from: <http://cs2016.statssa.gov.za/wp-content/uploads/2018/07/EasternCape.pdf>. Accessed March 28, 2024.
42. Sciences CfOoM. Proposed international guidelines for biomedical research involving human subjects. *Bull Med Ethics.* **1982**;1982:17–23.
43. Reddy SP, Mbewu AD, Williams DR, et al. Race, geographical location and other risk factors for hypertension: South African National Health and Nutrition Examination Survey 2011/12. *SSM Popul Health.* **2021**;16:100986. doi:10.1016/j.ssmph.2021.100986
44. World Health Organization. *WHO Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic*. World Health Organization; **2000**:1–253.
45. World Health Organization. *WHO European Regional Obesity Report 2022*. World Health Organization. Regional Office for Europe; **2022**.
46. World Health Organization. *Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation*. Geneva: World Health Organization; **2008**
47. Association AD. Standards of medical care in diabetes-2020 abridged for primary care providers. *Clin Diabetes.* **2020**;38(1):10.
48. Committee ADAPP, Committee: ADAPP. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. *Diabetes Care.* **2022**;45(Supplement\_1):S17–S38. doi:10.2337/dc22-S002
49. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation.* **2018**;137(12):e67–e492. doi:10.1161/CIR.0000000000000558
50. Sirugo G, Hennig BJ, Adeyemo AA, et al. Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. *Hum Genet.* **2008**;123(6):557. doi:10.1007/s00439-008-0511-y
51. Nshisso LD, Reese A, Gelaye B, Lemma S, Berhane Y, Williams MA. Prevalence of hypertension and diabetes among Ethiopian adults. *Diabetes Metab Syndr.* **2012**;6(1):36–41. doi:10.1016/j.dsx.2012.05.005
52. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. *World J Cardiol.* **2012**;4(5):135. doi:10.4330/wjc.v4.i5.135
53. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of professional and public education of the American heart association council on high blood pressure research. *Hypertension.* **2005**;45(1):142–161. doi:10.1161/01.HYP.0000150859.47929.8e
54. Masilela C, Pearce B, Ongole JJ, Adeniyi OV, Benjeddou M. Cross-sectional study of prevalence and determinants of uncontrolled hypertension among South African adult residents of Mkhondo municipality. *BMC Public Health.* **2020**;20(1):1–10. doi:10.1186/s12889-020-09174-7
55. Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. *Int J Obesity.* **2002**;26(1):48–57. doi:10.1038/sj.ijo.0801854
56. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. *J Hypert.* **2008**;26(5):831–843. doi:10.1097/HJH.0b013e3282f624a0
57. Redón J, Cea-Calvo L, Moreno B, et al. Independent impact of obesity and fat distribution in hypertension prevalence and control in the elderly. *J Hypert.* **2008**;26(9):1757–1764. doi:10.1097/HJH.0b013e3283077f03
58. Rudatsikira E, Muula AS, Mulenga D, Siziya S. Prevalence and correlates of obesity among Lusaka residents, Zambia: a population-based survey. *Int Arch Med.* **2012**;5(1):1–6. doi:10.1186/1755-7682-5-14
59. Parvanova A, Reseghetti E, Abbate M, Ruggerenti P. Mechanisms and treatment of obesity-related hypertension—Part 1: mechanisms. *Clin Kidney J.* **2024**;17(1):sfad282. doi:10.1093/ckj/sfad282
60. Owolabi EO, Ter Goon D, Adeniyi OV, Ajayi AI. Optimal waist circumference cut-off points for predicting metabolic syndrome among low-income black South African adults. *BMC Res Notes.* **2018**;11(1):1–5. doi:10.1186/s13104-018-3136-9
61. Al-Thani MH, Cheema S, Sheikh J, et al. Prevalence and determinants of metabolic syndrome in Qatar: results from a national health survey. *BMJ open.* **2016**;6(9):e009514. doi:10.1136/bmjopen-2015-009514
62. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? *Curr Atherosclerosis Rep.* **2012**;14(2):160–166. doi:10.1007/s11883-012-0227-2
63. Usui I. Common metabolic features of hypertension and type 2 diabetes. *Hypertens Res.* **2023**;46(5):1227–1233. doi:10.1038/s41440-023-01233-x
64. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. *J Clin Endocrinol Metab.* **2003**;88(4):1417–1427. doi:10.1210/jc.2002-021442
65. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabet Metab Syndr Obes.* **2014**;7:587. doi:10.2147/DMSO.S67400
66. Mbanya JCN, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-saharan Africa. *Lancet.* **2010**;375(9733):2254–2266. doi:10.1016/S0140-6736(10)60550-8

67. Godman B, Basu D, Pillay Y, et al. Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across Africa and the implications for the future. *Front Pharmacol.* **2020**;11:108. doi:10.3389/fphar.2020.00108
68. Welsh A, Hammad M, Piña IL, Kulinski J. Obesity and cardiovascular health. *Europ J Prevent Cardiol.* **2024**. doi:10.1093/eurjpc/zwae025
69. Padma G, Swapna N, Mamata M, Charita B, Padma T. Risk conferred by tagged SNPs of AGT gene in causing susceptibility to essential hypertension. *Ann Clin Exp Hypertens.* **2014**;36(8):579–585. doi:10.3109/10641963.2014.881845
70. Ji L, Cai X, Zhang L, et al. Association between polymorphisms in the renin-angiotensin-aldosterone system genes and essential hypertension in the Han Chinese population. *PLoS One.* **2013**;8(8):e72701. doi:10.1371/journal.pone.0072701
71. Al-Najai M, Muiya P, Tahir AI, et al. Association of the angiotensinogen gene polymorphism with atherosclerosis and its risk traits in the Saudi population. *BMC Cardiovasc Disord.* **2013**;13:17. doi:10.1186/1471-2261-13-17
72. Li H, Du Z, Zhang L, et al. The relationship between angiotensinogen gene polymorphisms and essential hypertension in a Northern Han Chinese population. *Angiology.* **2014**;65(7):614–619. doi:10.1177/0003319713491309
73. Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT. *Int J Hypertens.* **2013**;2013:578578. doi:10.1155/2013/578578
74. Li X, Tan H, Zhou S, et al. Renin-angiotensin-aldosterone system gene polymorphisms in gestational hypertension and preeclampsia: a case-control gene-association study. *Sci Rep.* **2016**;6(1):1–8. doi:10.1038/s41598-016-0001-8
75. Johnson AD, Newton-Cheh C, Chasman DI, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86 588 individuals. *Hypertension.* **2011**;57(5):903–910. doi:10.1161/HYPERTENSIONAHA.110.158667
76. Ji L, Li J, Yao B, Cai X, Shen Q, Xu J. Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genome-wide association studies. *J Human Hypertens.* **2017**;31(11):695–698. doi:10.1038/jhh.2017.29
77. L-q Z, Z-j W, Wei Y, et al. Polymorphisms of renin-angiotensin-aldosterone system gene in Chinese han patients with nonfamilial atrial fibrillation. *PLoS One.* **2015**;10(2):e0117489. doi:10.1371/journal.pone.0117489
78. Mopidevi B, Kaw MK, Sivankutty I, Jain S, Perla SK, Kumar A. A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice. *J Biol Chem.* **2019**;294(31):11829–11839. doi:10.1074/jbc.RA119.007715
79. Wu Y, Wang M, Zhang J, Sun N, Li C. A new model of the mechanism underlying lead poisoning: SNP in miRNA target region influence the AGT expression level. *Hereditas.* **2019**;156:6. doi:10.1186/s41065-019-0084-x
80. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *cell.* **1993**;75(5):843–854. doi:10.1016/0092-8674(93)90529-Y
81. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. *EMBO J.* **2004**;23(20):4051–4060. doi:10.1038/sj.emboj.7600385
82. Mopidevi B, Ponnala M, Kumar A. Human angiotensinogen+ 11525 C/A polymorphism modulates its gene expression through microRNA binding. *Physiol Genom.* **2013**;45(19):901–906. doi:10.1152/physiolgenomics.00056.2013
83. Ono M, Ochi T, Munekage K, et al. Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis. *Hepatol Res.* **2011**;41(12):1223–1229. doi:10.1111/j.1872-034X.2011.00883.x
84. Machal J, Novak J, Hezova R, et al. Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes. *Genes Nutr.* **2015**;10(5):488. doi:10.1007/s12263-015-0488-9
85. Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. *Circulation.* **2007**;115(6):725–732. doi:10.1161/circulationaha.106.642058
86. Furusawa T, Naka I, Yamauchi T, et al. Hypertension-susceptibility gene prevalence in the Pacific Islands and associations with hypertension in Melanesia. *J Hum Gen.* **2013**;58(3):142–149. doi:10.1038/jhg.2012.147

## Diabetes, Metabolic Syndrome and Obesity

Dovepress

### Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>